Arellano Luisa M, Arora Sukeshi Patel
Mays Cancer Center, UT Health Science Center San Antonio, 7979 Wurzbach Rd, MC 8026, San Antonio, TX 78229, USA.
J Nat Sci. 2018 Aug;4(8).
Over the past 30 years, the incidence in of hepatocellular carcinoma (HCC) in the United States has tripled, largely due to untreated chronic Hepatitis C virus, alcoholic hepatitis, and non-alcoholic steatohepatitis (NASH). Additionally, the incidence of HCC among South Texas Hispanics is higher than elsewhere in the United States. The median age of HCC is 62 years in United States and 67 years in South Texas, with over 30% being 70 years of age or older. However, there is limited data on how to treat older adults with advanced HCC. In this review, we will discuss treatment options for older adults with advanced HCC, further emphasizing the need for prospective studies in this population.
在过去30年里，美国肝细胞癌（HCC）的发病率增长了两倍，这主要归因于未经治疗的慢性丙型肝炎病毒、酒精性肝炎和非酒精性脂肪性肝炎（NASH）。此外，南德克萨斯州西班牙裔人群中HCC的发病率高于美国其他地区。在美国，HCC患者的中位年龄为62岁，在南德克萨斯州为67岁，其中超过30%的患者年龄在70岁及以上。然而，关于如何治疗老年晚期HCC患者的数据有限。在本综述中，我们将讨论老年晚期HCC患者的治疗选择，并进一步强调在这一人群中开展前瞻性研究的必要性。
